• June 3, 2020

Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings - Odessa American: Business

e-Edition Subscribe

Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings

Print
Font Size:
Default font size
Larger font size

Posted: Wednesday, May 20, 2020 6:01 am | Updated: 6:31 am, Wed May 20, 2020.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2020--

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that a total of six distinct abstracts on REBLOZYL ® (luspatercept-aamt) will be presented at the upcoming 2020 American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, held May 29-31, and at the 25 th Annual European Hematology Association (EHA25) Virtual Congress, held June 11-21.

Poster Presentations at ASCO20 Virtual Scientific Program

Title:

Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients (Pts) With Lower-Risk myelodysplastic syndromes (MDS) with Ring Sideroblasts (RS)- Abstract: #7518

Session:

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

 

 

Title:

Clinical Benefit of Luspatercept in Patients (Pts) With Lower-Risk MDS (LR-MDS) and High Transfusion Burden in the Phase 3 MEDALIST Study- Abstract: #7554

Session:

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Poster presentations and poster discussions will be available on demand through the ASCO20 Virtual Scientific Program beginning on May 29, 2020, at 8:00 a.m. EDT.

Presentations at EHA25 Virtual Congress

Title:

Assessment of Response to Luspatercept by β-Globin Genotype in Adult Patients With β-Thalassemia in the BELIEVE Trial - Abstract: Oral presentation S295

 

 

Title:

Assessment of Longer-Term Efficacy and Safety in the Phase 3 BELIEVE Trial of Luspatercept to Treat Anemia in Patients (Pts) with β-Thalassemia- Abstract: e-Poster 1548

 

 

Title:

Assessment of Dose-Dependent Response to Luspatercept in Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) With Ring Sideroblasts in the Phase 3 MEDALIST Trial - Abstract: e-Poster 812

 

 

Title:

Effects of Luspatercept on Serum Ferritin in Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (MDS) With Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial - Abstract: e-Poster 807

 

 

Title:

Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients (Pts) With Lower-Risk myelodysplastic syndromes (MDS) with Ring Sideroblasts (RS)- Abstract: e-Poster 813

 

 

Title:

Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study - Abstract: e-Poster 798

All e-Poster and oral abstract presentations will be made available on the on-demand EHA25 Virtual Congress Platform beginning on June 12, 2020 at 8:30 a.m. CEST.

About REBLOZYL ® (luspatercept-aamt)

REBLOZYL is the first and only U.S. Food and Drug Administration-approved erythroid maturation agent designed to promote red blood cell production through a novel mechanism. Luspatercept-aamt is being developed to treat anemia in patients with beta-thalassemia, MDS, and myelofibrosis. REBLOZYL is part of the global collaboration between Acceleron and Bristol Myers Squibb.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its commercialization, research, and development efforts in hematologic and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol Myers Squibb, are co-promoting REBLOZYL ® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States for the treatment of anemia in certain blood disorders. The Companies are also developing luspatercept for the treatment of anemia in patient populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on social media: @AcceleronPharma and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements about Acceleron’s strategy, future plans and prospects, including statements regarding the development and commercialization of Acceleron’s compounds, the timeline for clinical development and regulatory approval of Acceleron’s compounds, the expected timing for reporting of data from ongoing clinical trials, and the potential of Reblozyl ® (luspatercept-aamt) as a therapeutic drug. The words "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that the results of any clinical trials may not be predictive of the results or success of other clinical trials, that regulatory approval of Acceleron’s compounds in one indication or country may not be predictive of approval in another indication or country, that the development of Acceleron’s compounds will take longer and/or cost more than planned or accelerate faster than currently expected, that Acceleron or its collaboration partner, Bristol Myers Squibb Corporation (“BMS”), will be unable to successfully complete the clinical development of Acceleron’s compounds, that Acceleron or BMS may be delayed in initiating, enrolling or completing any clinical trials, and that Acceleron’s compounds will not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” included in Acceleron’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Acceleron has made and may make with the SEC in the future.

The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions, and projections with respect to future events, and Acceleron does not undertake and specifically disclaims any obligation to update any forward-looking statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200520005073/en/

CONTACT: Acceleron Pharma Inc.Investors:

Jamie Bernard, IRC, 617-649-9650

Associate Director, Investor RelationsMedia:

Matt Fearer, 617-301-9557

Director, Corporate Communications

KEYWORD: EUROPE UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH CLINICAL TRIALS OTHER HEALTH

SOURCE: Acceleron Pharma

Copyright Business Wire 2020.

PUB: 05/20/2020 07:00 AM/DISC: 05/20/2020 07:01 AM

http://www.businesswire.com/news/home/20200520005073/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
76°
Humidity: 60%
Winds: SSE at 14mph
Feels Like: 76°

Your Extended Forecast

Tomorrow

weather
High 90°/Low 67°
Partly cloudy. Lows overnight in the upper 60s.

wednesday

weather
High 94°/Low 70°
Mix of sun and clouds. Highs in the mid 90s and lows in the low 70s.

thursday

weather
High 98°/Low 70°
Mainly sunny. Highs in the upper 90s and lows in the low 70s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.